{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:55Z","timestamp":1786120255613,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/iae.0b013e31821e2207","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T14:44:48Z","timestamp":1317739488000},"page":"232-241","source":"Crossref","is-referenced-by-count":10,"title":["THE IMPACT OF TACROLIMUS ON GROWTH FACTORS IN EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY"],"prefix":"10.1097","volume":"32","author":[{"given":"Burak","family":"Turgut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Ustundag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulku","family":"Celiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusret","family":"Akpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20210130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.79.10.953","article-title":"Proliferative vitreoretinopathy: pathobiology, surgical management and adjunctive treatment.","volume":"79","author":"Charteris","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"R3-4-20210130","first-page":"171","article-title":"Treatment of intraocular proliferations with intravitreal steroids.","volume":"77","author":"Machemer","year":"1979","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R4-4-20210130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.eye.6700194","article-title":"Proliferative vitreoretinopathy developments in adjunctive treatment and retinal pathology.","volume":"16","author":"Charteris","year":"2002","journal-title":"Eye"},{"key":"R5-4-20210130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0002-9394(14)76889-8","article-title":"Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy.","volume":"111","author":"Lewis","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R7-4-20210130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","article-title":"Proliferative vitreoretinopathy: risk factors and pathobiology.","volume":"21","author":"Pastor","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"R8-4-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00011-004-1318-5","article-title":"A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis.","volume":"54","author":"Miyata","year":"2005","journal-title":"Inflamm Res"},{"key":"R9-4-20210130","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/00007890-199212000-00016","article-title":"The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes.","volume":"54","author":"Morikawa","year":"1992","journal-title":"Transplantation"},{"key":"R10-4-20210130","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/S0041-1345(98)00739-8","article-title":"Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506.","volume":"30","author":"Walgenbach","year":"1998","journal-title":"Transplant Proc"},{"key":"R11-4-20210130","doi-asserted-by":"crossref","first-page":"9430","DOI":"10.1074\/jbc.273.16.9430","article-title":"Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor.","volume":"273","author":"Lopez-Ilasaca","year":"1998","journal-title":"J Biol Chem"},{"key":"R12-4-20210130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0192-0561(99)00076-4","article-title":"FK506 inhibition of histamine release and cytokine production by mast cells and basophils.","volume":"22","author":"Sengoku","year":"2000","journal-title":"Int J Immunopharmacol"},{"key":"R13-4-20210130","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0041-1345(02)02895-6","article-title":"Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up.","volume":"34","author":"Savikko","year":"2002","journal-title":"Transplant Proc"},{"key":"R14-4-20210130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.intimp.2005.03.014","article-title":"FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells.","volume":"5","author":"Sasakawa","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"R15-4-20210130","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/j.lfs.2005.10.003","article-title":"Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells.","volume":"78","author":"Migita","year":"2006","journal-title":"Life Sci"},{"key":"R16-4-20210130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.imlet.2004.11.014","article-title":"FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fibroblasts.","volume":"98","author":"Migita","year":"2005","journal-title":"Immunol Lett"},{"key":"R17-4-20210130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/sj.bjp.0703472","article-title":"FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells.","volume":"130","author":"Sakuma","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R18-4-20210130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1567-5769(01)00008-X","article-title":"Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro.","volume":"1","author":"Sakuma","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"R19-4-20210130","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1016\/j.febslet.2006.10.019","article-title":"Immunophilin-ligands FK506 and CsA inhibit HIF1a expression by a VHL- and ubiquitin-independent mechanism.","volume":"580","author":"Kong","year":"2006","journal-title":"FEBS Lett"},{"key":"R20-4-20210130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2133.2005.06779.x","article-title":"FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor kappa B.","volume":"153","author":"Lan","year":"2005","journal-title":"Br J Dermatol"},{"key":"R21-4-20210130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/mcbr.1999.0108","article-title":"A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils.","volume":"1","author":"Kohyama","year":"1999","journal-title":"Mol Cell Biol Res Commun"},{"key":"R22-4-20210130","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/art.10215","article-title":"Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts.","volume":"46","author":"Cho","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R23-4-20210130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signalling.","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"R24-4-20210130","doi-asserted-by":"crossref","first-page":"29822","DOI":"10.1074\/jbc.271.47.29822","article-title":"Cellular response to transforming growth factor-beta1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions.","volume":"271","author":"Dinbergs","year":"1996","journal-title":"J Biol Chem"},{"key":"R25-4-20210130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/exer.1994.1081","article-title":"Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea.","volume":"59","author":"Wilson","year":"1994","journal-title":"Exp Eye Res"},{"key":"R26-4-20210130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1350-9462(99)00007-5","article-title":"Growth factors: importance in wound healing and maintenance of transparency of the cornea.","volume":"19","author":"Imanishi","year":"2000","journal-title":"Prog Retin Eye Res"},{"key":"R27-4-20210130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/exer.1997.0338","article-title":"Effect of transforming growth factor-beta 1 and -beta 2 on in vitro rabbit corneal epithelial cell proliferation promoted by epidermal growth factor, keratinocyte growth factor, or hepatocyte growth factor.","volume":"65","author":"Honma","year":"1997","journal-title":"Exp Eye Res"},{"key":"R28-4-20210130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1350-9462(01)00008-8","article-title":"The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells.","volume":"20","author":"Wilson","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"R29-4-20210130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1006\/exer.2002.2066","article-title":"TGF beta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF beta, PDGF and integrin signaling.","volume":"75","author":"Jester","year":"2002","journal-title":"Exp Eye Res"},{"key":"R30-4-20210130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/joe.0.1320011","article-title":"The role of insulin like growth factor 1 and insulin like growth factor binding protein in the control of human fetal growth.","volume":"132","author":"Wang","year":"1992","journal-title":"J Endocrinol"},{"key":"R31-4-20210130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2359","article-title":"Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.","volume":"6","author":"Clemmons","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R32-4-20210130","first-page":"2157","article-title":"A new model of proliferative vitreoretinopathy.","volume":"39","author":"Frenzel","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R33-4-20210130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/exer.2002.2031","article-title":"A mouse model of PVR induced by dispase.","volume":"77","author":"Valeria Canto","year":"2002","journal-title":"Exp Eye Res"},{"key":"R34-4-20210130","first-page":"34","article-title":"Experiment study of retinal ultrastructure after intravitreal FK506.","volume":"20","author":"Li","year":"2004","journal-title":"Yan Ke Xue Bao"},{"key":"R35-4-20210130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/bjo.2006.103168","article-title":"Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats.","volume":"91","author":"Oh-i","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R36-4-20210130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0002-9394(14)77369-6","article-title":"A comparison of different cellular inocula in an experimental model of massive periretinal proliferation.","volume":"93","author":"Fastenberg","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R37-4-20210130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/02713680600932142","article-title":"Effects of intravitreal dispase on vitreoretinal interface in rabbits.","volume":"31","author":"Dongqing","year":"2006","journal-title":"Curr Eye Res"},{"key":"R38-4-20210130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-9394(83)90453-1","article-title":"Ocular toxicity of fluorouracil after vitrectomy.","volume":"96","author":"Stern","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"R39-4-20210130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF00936524","article-title":"Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.","volume":"231","author":"Steinhorst","year":"1993","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R40-4-20210130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s004170050376","article-title":"Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy studies.","volume":"238","author":"Imai","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R41-4-20210130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.V1061366","article-title":"Newer immunosuppressive drugs: a review.","volume":"10","author":"Gummert","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R42-4-20210130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0041-1345(98)00216-4","article-title":"Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.","volume":"30","author":"Jensik","year":"1998","journal-title":"Transplant Proc"},{"key":"R43-4-20210130","first-page":"1833","article-title":"FK506 attenuates early ischemic neuronal death in a monkey model of stroke.","volume":"42","author":"Takamatsu","year":"2001","journal-title":"J Nucl Med"},{"key":"R44-4-20210130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaad.2005.04.059","article-title":"The efficacy and safety of tacrolimus ointment: a clinical review.","volume":"53","author":"Beck","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R45-4-20210130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1378\/chest.104.1.309","article-title":"Pulmonary infiltrates recovered by FK506 in a patient with Behcets disease.","volume":"104","author":"Koga","year":"1993","journal-title":"Chest"},{"key":"R46-4-20210130","first-page":"802","article-title":"A phase II trial of FK 506 (tacrolimus) on refractory uveitis associated with Behcets disease and allied conditions.","volume":"35","author":"Sakane","year":"1995","journal-title":"Ryumachi"},{"key":"R47-4-20210130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0002-9394(81)90171-9","article-title":"Glucocorticoid inhibition of intraocular proliferation after injury.","volume":"91","author":"Tano","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"R48-4-20210130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0002-9394(14)76037-4","article-title":"The effect of triamcinolone acetonide on a refine experimental model of proliferative vitreoretinopathy.","volume":"99","author":"Chandler","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"R49-4-20210130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","article-title":"Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.","volume":"90","author":"Tano","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"R50-4-20210130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02150144","article-title":"Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment.","volume":"225","author":"Chandler","year":"1987","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R51-4-20210130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/0002-9394(82)90239-2","article-title":"Fluoro-uracil for the treatment of massive perineurial proliferation.","volume":"94","author":"Blumenkranz","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R52-4-20210130","first-page":"252","article-title":"Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.","volume":"19","author":"Joondeph","year":"1988","journal-title":"Ophthalmic Surg"},{"key":"R53-4-20210130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00006982-199313030-00011","article-title":"Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy.","volume":"13","author":"Arroyo","year":"1993","journal-title":"Retina"},{"key":"R54-4-20210130","first-page":"520","article-title":"Cishydroxyproline inhibits proliferation, collagen synthesis, attachment and migration of cultured bovine retinal pigment epithelial cells.","volume":"38","author":"Yoo","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R55-4-20210130","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/archopht.1986.01050200132067","article-title":"Oral colchicine for the treatment of experimental traction retinal detachment.","volume":"8","author":"Lemor","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"R56-4-20210130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-2952(94)00423-J","article-title":"Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin.","volume":"49","author":"Richter","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"R57-4-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000052604","article-title":"Interleukin-2-dependent mechanisms are involved in the development of glomerulosclerosis after partial renal ablation in rats.","volume":"9","author":"Hamar","year":"2001","journal-title":"Exp Nephrol"},{"key":"R58-4-20210130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1183\/09031936.06.00070705","article-title":"Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis.","volume":"27","author":"Nagano","year":"2006","journal-title":"Eur Respir J"},{"key":"R59-4-20210130","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1365-2168.2000.01576.x","article-title":"Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury.","volume":"87","author":"Jain","year":"2000","journal-title":"Br J Surg"},{"key":"R60-4-20210130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study.","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R61-4-20210130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1523-1755.2005.00461.x","article-title":"Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study.","volume":"68","author":"Mok","year":"2005","journal-title":"Kidney Int"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-201202000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:21:19Z","timestamp":1786047679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-201202000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e31821e2207","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}